RxDoctor Payments Data

Alan Schliftman, MD

Procedural Dermatology · White Plains, NYNPI 1164598108

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Botanix SB Inc at 29.3% of the total. That places this record below the midpoint for procedural dermatology clinicians in NY, where the typical reported total is $3,601.

$426in general payments, 2019–2025

Across 7 payments — averaging $60.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Botanix SB Inc$125
  • AbbVie$125
  • Janssen Scientific Affairs, LLC$111
  • Novartis$37
  • Johnson & Johnson$29

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426 in reported general payments places this provider in the 25th percentile of 69 procedural dermatology providers in New York.

See all procedural dermatology providers in New York

Medicare billing

Part B allowed, 2024
$254,713
Medicare patients
982
Services billed
4,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$391,213
StelaraUstekinumab11$187,964
Humira(Cf) PenAdalimumab12$101,844
Dupixent SyringeDupilumab17$62,060
Fluorouracil119$8,124
Clobetasol Propionate166$6,915
Betamethasone Dipropionate146$5,956
Fluocinonide79$2,759
Ketoconazole224$2,506
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip115$2,416
Clindamycin Phosphate26$2,020
Metronidazole34$1,971
Doxycycline Monohydrate43$1,947
Tretinoin28$1,364
Doxycycline Hyclate32$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$29$187,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 69 procedural dermatology providers in New York.

Other procedural dermatology in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →